Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Hypoxic-ischemic encephalopathy
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
May 09, 2025
Update - Notification of buy-back - NEU
May 08, 2025
Update - Notification of buy-back - NEU
May 08, 2025
DAYBUE Q1 2025 net sales US$84.6m up 11% from Q1 2024
May 07, 2025
Update - Notification of buy-back - NEU
May 06, 2025
Notification of cessation of securities - NEU
May 06, 2025
Update - Notification of buy-back - NEU
May 05, 2025
Becoming a substantial holder
May 05, 2025
Update - Notification of buy-back - NEU
May 02, 2025
Neuren appoints Daryl DeKarske to executive team
May 02, 2025
Update - Notification of buy-back - NEU
1
2
3
4
5
6
7
8
Next
